Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease.

ABSTRACT:

Introduction

Alzheimer's disease (AD) is associated with synapse loss. Souvenaid, containing the specific nutrient combination Fortasyn Connect, was designed to improve synapse formation and function. The NL-ENIGMA study explored the effect of Souvenaid on synapse function in early AD by assessing cerebral glucose metabolism (CMRglc) with ¹⁸F-fluorodeoxyglucose ([¹⁸F]FDG) positron emission tomography (PET).

Methods

We conducted an exploratory double-blind randomized controlled single-center trial. Fifty patients with mild cognitive impairment or mild dementia with evidence of amyloid pathology (cerebrospinal fluid or PET) were stratified for MMSE (20-24 and 25-30) and randomly 1:1 allocated to 24-week daily administration of 125 mL Souvenaid (n = 25) or

SUBMITTER: Scheltens NME 

PROVIDER: S-EPMC6804721 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature